Zonal Officers gets authorization from the Drug Controller General of India (DCGI) to sign test licenses in Form 11 of the Drugs and Cosmetic Rules, 1945 which is used for importing small quantities of drugs for the purpose of conducting bioavailability/bioequivaience (BA/BE) study. On the subject, in the continuation of orders from office on 30.09.2014, 16.10.2014 and 06.01.2015, the decision is made to change the delegation of power as the signing authority in test licenses in Form 11 is granted to zonal offices of Central Drugs Standard Control Organisation (CDSCO). CDSCO is the Indian regulatory body under which medical devices are regulated in India. Learn more about registration of medical devices in South East Asia markets.
The order from DCGI read “The zonal officer are hereby authorised/delegated to sign test licenses in Form 11 of the Drugs and Cosmetics Rules, 1945 for import of small quantities of drugs which are approved for more than four years in the country intended for conducting BA/BE study for the purpose of export in healthy human volunteers”. The zonal offices received this power under Rule 22 of Drug and Cosmetics Rules, 1945. READ ALSO: CDSCO India Authorized Agents for medical device registration.
Other News
CDSCO Issues Guidelines on Medical Device License Retention
New Delhi, May 15, 2024 — The Central Drugs Standard Control Organization (CDSCO) has released a circular (F. No. MED-15/35/2024-eOffice) on the retention of medical device licenses and certificates under the Medical Devices Rules, 2017. […]
Read MoreIndia Medical Device Pricing Strategy: Ensuring Growth & Affordability
India’s National Pharmaceutical Pricing Authority (NPPA) is developing a specialized India medical device pricing strategy for medical devices, transitioning away from the conventional drug-centric framework. This innovative strategy will incorporate international pricing tactics tailored to […]
Read MoreImports of High-Value Medical Equipment
High-Value Medical Equipment The Central Drugs Standard Control Organization (CDSCO) and the Central Board of Indirect Taxes & Customs have released a new circular, “F.No.401/40/2021-Cus.III,” detailing updated policies on the import of used high-end medical […]
Read MoreSEC Committee: Pioneering Medical Approvals
New important article released by Central Drugs Standard Control Organization (CDSCO) titled “SEC – Special Expert Committee, Medical Devices”. Key highlights include the streamlined processes for CDSCO application evaluations, preparation and significance of briefing materials, […]
Read MoreErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read More